Gender differences in lung cancer studied

WASHINGTON -- Lung cancer acts differently in women than in men, and major new studies are exploring whether estrogen is a key reason -- and whether harnessing the hormone might help fight the number one cancer killer.

The gender link may sound surprising. After all, ask women what cancer they worry most about and surveys show breast cancer consistently tops the list, while lung cancer is seldom mentioned.

Yet lung cancer is increasingly a women's problem. It will claim more than 162,000 lives this year, 72,000 of them women. That's more women than are killed by breast, ovarian, uterine, and cervical cancers combined.

While male deaths from lung cancer have been dropping since 1991, women's death rates are stubbornly holding steady. Much of that difference is attributed to gender variations in smoking, the main cause of lung cancer.

Women tend to get different kinds of lung cancer than men. While it is unclear whether they are at greater risk of developing the disease, some research suggests that they may absorb more cancer-causing chemicals from cigarettes and become sick after smoking less. Among people who never smoked, more women than men are diagnosed with lung cancer.

On the other hand, women tend to survive lung cancer slightly better than their male counterparts. And some of the newest lung cancer drugs, Tarceva and Iressa, seem to work more often in women.

Teasing out the biology behind the gender differences could lead to improved treatment for everyone, said Dr. Kathy Albain, a lung cancer specialist at Loyola University Health System.

She is heading a National Cancer Institute-funded study that is recruiting 720 newly diagnosed lung cancer patients to examine what hormones, genes, or other molecular factors explain why lung cancer behaves differently in men and women, smokers and nonsmokers. ``We're learning what's going on in the lung, and whether or not this is a real thing that can be exploited for cancer treatment," she said.

Estrogen already is a leading suspect. Two provocative studies are getting underway:

Research by University of Pittsburgh pharmacologist Jill Siegfried suggests that estrogen may act as a fuel for lung tumors just like it does for many breast tumors, and that blocking estrogen with the same drugs that breast cancer patients use might also work in the lungs. A 120-patient study at Pittsburgh and the University of California, Los Angeles, will test whether women fare better when given the anti-estrogen drug Faslodex and the lung cancer drug Tarceva.

The second study, involving 600 women, tests an experimental drug called Xyotax that may need estrogen to work. Seattle-based Cell Therapeutics Inc. reformulated the older cancer drug Taxol, covering it with a protein designed to let it reach the lungs with fewer side effects. In three large studies, this new Xyotax didn't seem to improve survival over older competitors -- until researchers checked gender effects. About 45 percent of women given Xyotax survived lung cancer for a year, compared with just 25 percent of women given standard drugs or men given either regimen.